Medicals Direct Screenings Limited
Annual Report and Financial Statements
For the year ended 31 December 2024
Company Registration No. 02706045 (England and Wales)
Medicals Direct Screenings Limited
Company Information
Directors
J Benton
D Oatley
Company number
02706045
Registered office
Unit 10 Millars Brook Business Park
Molly Millars Lane
Wokingham
Berkshire
RG41 2AD
Auditor
Moore Kingston Smith LLP
Orbital House
20 Eastern Road
Romford
Essex
RM1 3PJ
Medicals Direct Screenings Limited
Contents
Page
Directors' report
1 - 2
Independent auditor's report
3 - 6
Profit and loss account
7
Balance sheet
8
Notes to the financial statements
9 - 16
Medicals Direct Screenings Limited
Directors' Report
For the year ended 31 December 2024
Page 1

The directors present their annual report and financial statements for the year ended 31 December 2024.

Principal activities

The principal activity of the company continued to be that of providing health screening information for the

life insurance industry.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

J Benton
D Oatley
Auditor

Moore Kingston Smith LLP were appointed as auditor to the company and in accordance with section 485 of the Companies Act 2006, a resolution proposing that they be re-appointed will be put at a General Meeting.

Statement of directors' responsibilities

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

 

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

 

 

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Medicals Direct Screenings Limited
Directors' Report (Continued)
For the year ended 31 December 2024
Page 2
Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.

Small companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the board
J Benton
Director
10 June 2025
2025-06-10
Medicals Direct Screenings Limited
Independent Auditor's Report
To the Members of Medicals Direct Screenings Limited
Page 3
Opinion

We have audited the financial statements of Medicals Direct Screenings Limited (the 'company') for the year ended 31 December 2024 which comprise the Profit and Loss Account, the Balance Sheet and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

 

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Medicals Direct Screenings Limited
Independent Auditor's Report (Continued)
To the Members of Medicals Direct Screenings Limited
Page 4

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

 

Responsibilities of directors

As explained more fully in the Directors' Responsibilities Statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

 

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Medicals Direct Screenings Limited
Independent Auditor's Report (Continued)
To the Members of Medicals Direct Screenings Limited
Page 5
Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

 

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

 

 

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

 

 

Medicals Direct Screenings Limited
Independent Auditor's Report (Continued)
To the Members of Medicals Direct Screenings Limited
Page 6

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the company.

Our approach was as follows:

 

 

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Karen Wardell
Senior Statutory Auditor
for and on behalf of Moore Kingston Smith LLP
10 June 2025
Chartered Accountants
Statutory Auditor
Orbital House
20 Eastern Road
Romford
Essex
RM1 3PJ
Medicals Direct Screenings Limited
Profit and Loss Account
For the year ended 31 December 2024
Page 7
2024
2023
Notes
£
£
Turnover
3,137,203
3,997,173
Cost of sales
(2,465,439)
(3,497,937)
Gross profit
671,764
499,236
Administrative expenses
(668,325)
(979,916)
Exceptional item
3
(768,627)
(4,509)
Loss before taxation
(765,188)
(485,189)
Tax on loss
(4,364)
70,902
Loss for the financial year
(769,552)
(414,287)
Medicals Direct Screenings Limited
Balance Sheet
As at 31 December 2024
Page 8
2024
2023
Notes
£
£
£
£
Fixed assets
Intangible assets
5
130,600
222,789
Tangible assets
6
1,226
7,419
Investments
7
1,000
1,000
132,826
231,208
Current assets
Debtors
9
308,957
356,366
Cash at bank and in hand
13,472
130,993
322,429
487,359
Creditors: amounts falling due within one year
10
(1,411,808)
(905,568)
Net current liabilities
(1,089,379)
(418,209)
Net liabilities
(956,553)
(187,001)
Capital and reserves
Called up share capital
11
14,001
14,001
Share premium account
33,499
33,499
Profit and loss reserves
(1,004,053)
(234,501)
Total equity
(956,553)
(187,001)

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 10 June 2025 and are signed on its behalf by:
J Benton
Director
Company Registration No. 02706045
Medicals Direct Screenings Limited
Notes to the Financial Statements
For the year ended 31 December 2024
Page 9
1
Accounting policies
Company information

Medicals Direct Screenings Limited is a private company limited by shares incorporated in England and Wales. The registered office is Unit 10 Millars Brook Business Park, Molly Millars Lane, Wokingham, Berkshire, RG41 2AD.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

The directors have prepared and reviewed forecasts including cash flow projections for a period of 12 months from the date of signing and are satisfied that the Company will be able to continue in operation and meet it's liabilities as they fall due. Inuvi Health Limited has indicated it will continue to provide further financial and other support to Medicals Direct Screenings Limited for at least the next 12 months from the date of signing and will not call upon repayment of the intercompany balance within that time.

 

At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

Medicals Direct Screenings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2024
1
Accounting policies
(Continued)
Page 10
1.4
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a straight line basis over its expected life, which is 10 years.

 

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
25% Reducing balance
Computer equipment
33% Straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.7
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Medicals Direct Screenings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2024
1
Accounting policies
(Continued)
Page 11

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.8
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Medicals Direct Screenings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2024
1
Accounting policies
(Continued)
Page 12
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.11
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

Medicals Direct Screenings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2024
1
Accounting policies
(Continued)
Page 13
1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.

Valuation of Goodwill

The annual amortisation charge for intangible assets is sensitive to changes in the estimated lives and residual values of the assets. The useful economic lives and residual values are re-assessed annually.

 

Goodwill impairment reviews are also performed annually. These reviews require an estimation of the value in use of the cash generating units to which goodwill has been allocated. The value in use calculation requires the entity to estimate the future cash flows expected to arise for the cash generating unit and a suitable discount rate to calculate present value.

 

See note 5 for the carrying amount of the intangible assets and notes 1.3 and 1.4 for the useful economic lives for each class of asset.

3
Exceptional item
2024
2023
£
£
Expenditure
Exceptional items
768,627
-
Medicals Direct Screenings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2024
3
Exceptional item
(Continued)
Page 14

These exceptional items relate to restructuring costs due to the acquisition of the company by Inuvi Health Limited.

4
Employees

The average monthly number of persons employed by the company during the year was 32 (2023:47).

5
Intangible fixed assets
Goodwill
£
Cost
At 1 January 2024 and 31 December 2024
909,175
Amortisation and impairment
At 1 January 2024
686,386
Amortisation charged for the year
92,189
At 31 December 2024
778,575
Carrying amount
At 31 December 2024
130,600
At 31 December 2023
222,789
6
Tangible fixed assets
Fixtures and fittings
Computer equipment
Total
£
£
£
Cost
At 1 January 2024 and 31 December 2024
590
86,182
86,772
Depreciation and impairment
At 1 January 2024
407
78,946
79,353
Depreciation charged in the year
20
6,173
6,193
At 31 December 2024
427
85,119
85,546
Carrying amount
At 31 December 2024
163
1,063
1,226
At 31 December 2023
183
7,236
7,419
Medicals Direct Screenings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2024
Page 15
7
Fixed asset investments
2024
2023
£
£
Shares in group undertakings and participating interests
1,000
1,000
8
Subsidiaries

Details of the company's subsidiaries at 31 December 2024 are as follows:

Name of undertaking
Registered office
Class of
% Held
shares held
Direct
Medicals Direct Screening Services Limited
Unit 10 Millars Brook Business Park, Molly Millars Lane, Wokingham, Berkshire, England, RG41 2AD
Ordinary
100.00
9
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
246,439
282,897
Prepayments and accrued income
35,894
42,481
282,333
325,378
2024
2023
Amounts falling due after more than one year:
£
£
Deferred tax asset
26,624
30,988
Total debtors
308,957
356,366
10
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
46,654
176,828
Amounts owed to group undertakings
1,189,291
601,069
Taxation and social security
11,959
62,138
Other creditors
-
11,120
Accruals and deferred income
163,904
54,413
1,411,808
905,568
Medicals Direct Screenings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2024
Page 16
11
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
14,001
14,001
14,001
14,001
12
Financial commitments, guarantees and contingent liabilities

Santander UK PLC holds a fixed and floating charge over the assets of the company, as the company acts as a guarantor for the bank loan taken out by the Inuvi Group.

13
Operating lease commitments

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2024
2023
£
£
Within one year
-
0
16,140
Between two and five years
-
0
6,399
-
0
22,539
14
Related party transactions

The company is a wholly owned subsidiary of Inuvi Group Limited (formerly Longacre MSS Group Limited) and has taken advantage of the exemption conferred by FRS 102 not to disclose transactions with Inuvi Group Limited (formerly Longacre MSS Group Limited) or other wholly owned subsidiaries within the group.

15
Parent company

The parent company is Inuvi Health Limited, a company incorporated in England and Wales, which owns 100% of the issued share capital of the company. The intermediate parent company is Inuvi Group Limited.

 

The ultimate parent company is Longacre Group Limited, a company incorporated in England and Wales.

 

Inuvi Group Limited. is the smallest group to prepare consolidated financial statements. Longacre Group Limited is the largest group to prepare consolidated financial statements which include these financial statements. Copies of the consolidated financial statements can be obtained from 1 Mercer Street, London, WC2H 9QJ.

2024-12-312024-01-01falsefalsefalseCCH SoftwareCCH Accounts Production 2025.100J BentonD Oatley027060452024-01-012024-12-3102706045bus:Director12024-01-012024-12-3102706045bus:Director22024-01-012024-12-3102706045bus:RegisteredOffice2024-01-012024-12-31027060452024-12-31027060452023-01-012023-12-3102706045core:Exceptional12024-01-012024-12-3102706045core:Exceptional12023-01-012023-12-31027060452023-12-3102706045core:NetGoodwill2024-12-3102706045core:NetGoodwill2023-12-3102706045core:FurnitureFittings2024-12-3102706045core:ComputerEquipment2024-12-3102706045core:FurnitureFittings2023-12-3102706045core:ComputerEquipment2023-12-3102706045core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3102706045core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3102706045core:ShareCapital2024-12-3102706045core:ShareCapital2023-12-3102706045core:SharePremium2024-12-3102706045core:SharePremium2023-12-3102706045core:RetainedEarningsAccumulatedLosses2024-12-3102706045core:RetainedEarningsAccumulatedLosses2023-12-3102706045core:ShareCapitalOrdinaryShareClass12024-12-3102706045core:ShareCapitalOrdinaryShareClass12023-12-3102706045core:Goodwill2024-01-012024-12-3102706045core:FurnitureFittings2024-01-012024-12-3102706045core:ComputerEquipment2024-01-012024-12-3102706045core:NetGoodwill2023-12-3102706045core:NetGoodwill2024-01-012024-12-3102706045core:FurnitureFittings2023-12-3102706045core:ComputerEquipment2023-12-31027060452023-12-3102706045core:Subsidiary12024-01-012024-12-3102706045core:Subsidiary112024-01-012024-12-3102706045core:CurrentFinancialInstruments2024-12-3102706045core:CurrentFinancialInstruments2023-12-3102706045core:AfterOneYear2024-12-3102706045core:AfterOneYear2023-12-3102706045bus:OrdinaryShareClass12024-01-012024-12-3102706045bus:OrdinaryShareClass12024-12-3102706045bus:OrdinaryShareClass12023-12-3102706045core:WithinOneYear2024-12-3102706045core:WithinOneYear2023-12-3102706045core:BetweenTwoFiveYears2024-12-3102706045core:BetweenTwoFiveYears2023-12-3102706045bus:PrivateLimitedCompanyLtd2024-01-012024-12-3102706045bus:FRS1022024-01-012024-12-3102706045bus:Audited2024-01-012024-12-3102706045bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP